Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
IOVA Iovance Biotherapeutics, Inc. daily Stock Chart
IOVA [NASD]
Iovance Biotherapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.27 Insider Own1.14% Shs Outstand125.02M Perf Week6.52%
Market Cap3.18B Forward P/E- EPS next Y-1.40 Insider Trans0.00% Shs Float122.68M Perf Month13.81%
Income-134.00M PEG- EPS next Q-0.29 Inst Own- Short Float10.84% Perf Quarter134.96%
Sales- P/S- EPS this Y10.00% Inst Trans0.81% Short Ratio6.65 Perf Half Y172.12%
Book/sh3.52 P/B7.24 EPS next Y-17.60% ROA-35.80% Target Price33.63 Perf Year78.11%
Cash/sh3.52 P/C7.24 EPS next 5Y- ROE-37.60% 52W Range7.26 - 26.07 Perf YTD187.80%
Dividend- P/FCF- EPS past 5Y18.20% ROI- 52W High-2.30% Beta1.81
Dividend %- Quick Ratio20.10 Sales past 5Y- Gross Margin- 52W Low250.83% ATR1.23
Employees88 Current Ratio20.10 Sales Q/Q- Oper. Margin- RSI (14)67.42 Volatility4.90% 5.36%
OptionableYes Debt/Eq0.00 EPS Q/Q4.80% Profit Margin- Rel Volume0.60 Prev Close25.78
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume2.00M Price25.47
Recom1.60 SMA207.51% SMA5030.64% SMA200106.47% Volume1,193,391 Change-1.20%
Apr-29-19Initiated Piper Jaffray Overweight $20
Feb-28-19Reiterated Chardan Capital Markets Buy $30 → $20
Feb-07-19Initiated Robert W. Baird Outperform
Dec-31-18Resumed B. Riley FBR Buy $24
Jul-06-18Reiterated Chardan Capital Markets Buy
Apr-10-18Upgrade B. Riley FBR, Inc. Neutral → Buy $22
Mar-13-18Reiterated B. Riley FBR, Inc. Neutral $18.50 → $22
Feb-23-18Downgrade B. Riley FBR, Inc. Buy → Neutral $18 → $18.50
Jan-25-18Reiterated H.C. Wainwright Buy $16 → $22
Nov-01-17Reiterated B. Riley FBR, Inc. Buy $17.50 → $18
Jul-18-19 08:00AM  Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer GlobeNewswire +5.31%
Jul-10-19 12:46PM  Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price? Simply Wall St.
Jul-08-19 06:22PM  Here's Why Iovance Biotherapeutics Soared 50% in June Motley Fool
Jul-02-19 08:50AM  Iovance stock up 2% after company gives positive regulatory update on potential cervical cancer treatment MarketWatch
07:30AM  Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) GlobeNewswire
Jun-25-19 09:21AM  3 Stocks With a Perfect Smart Score TipRanks
Jun-24-19 03:00PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Jun-19-19 01:58PM  Harry Boxers three biotech stocks on the move include Nektar Therapeutics MarketWatch
Jun-18-19 09:51AM  Cancer Therapy Stocks Soar After Pfizer Deal Investopedia
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-17-19 03:37PM  Why Iovance Biotherapeutics Stock Jumped Today Motley Fool +14.92%
Jun-14-19 09:08AM  Did Hedge Funds Drop The Ball On Iovance Biotherapeutics, Inc. (IOVA) ? Insider Monkey
Jun-12-19 10:30AM  PHIO: Two Compounds Entering Clinic in 2020 Zacks Small Cap Research
Jun-11-19 07:00AM  Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors GlobeNewswire -5.02%
Jun-05-19 03:11PM  Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
08:00AM  Iovance and Amgen Are Making Cancer History Bloomberg
Jun-03-19 04:21PM  Why Iovance Biotherapeutics Stock Jumped Today Motley Fool +10.34%
02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
01:22PM  Oncology Stock Expected to Double (Again) Schaeffer's Investment Research
May-31-19 07:00AM  Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte (TIL) Therapy GlobeNewswire -8.30%
06:59AM  Iovance Biotherapeutics to Participate in Upcoming Conferences in June GlobeNewswire
May-29-19 08:00AM  Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products GlobeNewswire
May-23-19 04:09PM  How This Small Biotech Could Take On Merck In Cervical Cancer Drugs Investor's Business Daily
07:37AM  The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut Benzinga
May-22-19 10:24AM  Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options Zacks
09:20AM  Investors Who Bought Iovance Biotherapeutics (NASDAQ:IOVA) Shares Three Years Ago Are Now Up 173% Simply Wall St.
May-19-19 09:00AM  3 Biotech Stocks That Soared Last Week: Are They Buys? Motley Fool
May-16-19 04:29PM  Why Snap, Kemet, and Iovance Biotherapeutics Jumped Today Motley Fool +36.06%
04:14PM  Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting Investor's Business Daily
02:47PM  Here's Why Iovance Biotherapeutics Soared Today Motley Fool
12:30PM  Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward Benzinga
07:40AM  The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics Benzinga
May-15-19 05:27PM  Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs GlobeNewswire
May-08-19 05:23AM  Iovance Biotherapeutics, Inc. (IOVA) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 05:13PM  Iovance Biotherapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-03-19 09:01AM  Heres What Hedge Funds Think About Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
May-02-19 07:00AM  Iovance Biotherapeutics to Participate in Upcoming Conferences in May GlobeNewswire
May-01-19 07:00AM  Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019 GlobeNewswire
Apr-22-19 10:15AM  PHIO: Activation in the Tumor Microenvironment Zacks Small Cap Research
Apr-03-19 04:18PM  Here's Why Iovance Biotherapeutics Soared on Wednesday Motley Fool +20.41%
07:05AM  Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting GlobeNewswire
07:00AM  Iovance Biotherapeutics Announces Clinical Programs Update GlobeNewswire
Apr-02-19 07:00AM  Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma GlobeNewswire
Apr-01-19 08:00AM  Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel GlobeNewswire
Mar-29-19 08:23AM  Iovance Biotherapeutics Announces April Scientific and Investor Presentations GlobeNewswire
Mar-26-19 11:57AM  Did Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Insiders Buy Up More Shares? Simply Wall St.
Mar-06-19 07:00AM  Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March GlobeNewswire -8.05%
Feb-27-19 08:02PM  Iovance Biotherapeutics, Inc. (IOVA) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-26-19 07:00AM  Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer GlobeNewswire
Feb-22-19 07:00AM  Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019 GlobeNewswire
Feb-05-19 08:53AM  Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Trading At A 49.98% Discount Simply Wall St. -5.19%
Feb-04-19 12:20PM  Stocks Moving After Hours: Seagate, STMicroelectronics, Google, Legg Mason Investing.com +8.21%
Feb-01-19 07:00AM  Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences GlobeNewswire
Jan-04-19 09:02AM  2 Promising Biotech Stocks That Insiders Are Snapping Up TheStreet.com +7.20%
Dec-21-18 07:00AM  Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -7.63%
Dec-14-18 10:00AM  Here's a Handful of Small Biotechs Where Insiders Are Buying TheStreet.com
Dec-12-18 02:28AM  Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy? Insider Monkey
Dec-10-18 07:48AM  Insider Buys Of The Week: Iovance, Mohawk, United Continental Benzinga +12.04%
Dec-05-18 09:21AM  What Kind Of Shareholders Own Iovance Biotherapeutics Inc (NASDAQ:IOVA)? Simply Wall St.
Nov-13-18 08:01AM  Iovance Biotherapeutics to Participate at November Investor Conferences GlobeNewswire
Nov-06-18 05:35PM  Iovance Biotherapeutics: 3Q Earnings Snapshot Associated Press -6.88%
04:01PM  Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire
Oct-31-18 03:38PM  Nantahala Capital Managements Returns, AUM, and Holdings Insider Monkey
Oct-30-18 08:01AM  Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018 GlobeNewswire
Oct-29-18 08:00AM  Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018 GlobeNewswire
Oct-18-18 07:00AM  Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe GlobeNewswire
Oct-17-18 07:00AM  Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering GlobeNewswire
Oct-15-18 04:53PM  Why Iovance Biotherapeutics, Inc. Is Sinking Today Motley Fool -10.39%
Oct-12-18 04:33PM  Why Canopy Growth, SSR Mining, and Iovance Biotherapeutics Jumped Today Motley Fool +19.66%
07:45AM  Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock GlobeNewswire
07:34AM  The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program Benzinga
Oct-11-18 04:05PM  Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
04:01PM  Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Companys Clinical Program GlobeNewswire
Sep-26-18 08:01AM  Iovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire -5.22%
Sep-12-18 10:30AM  Immuno Oncology & Targeted Therapy Companies Set to Breakout ACCESSWIRE
Sep-07-18 08:00AM  Todays Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics ACCESSWIRE
Sep-06-18 03:49PM  Why Iovance Biotherapeutics Stock Is Crashing Today Motley Fool -24.78%
12:49PM  Biotech Dives After Experimental Lung Cancer Regimen Disappoints Investor's Business Daily
Sep-05-18 08:44AM  Are Options Traders Betting on a Big Move in Lion Biotechnologies (IOVA) Stock? Zacks
Aug-16-18 08:01AM  Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center GlobeNewswire
Aug-06-18 04:05PM  Iovance Biotherapeutics: 2Q Earnings Snapshot Associated Press +6.18%
04:01PM  Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Iovance Biotherapeutics Inc to Host Earnings Call ACCESSWIRE
Jul-30-18 08:01AM  Iovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018 GlobeNewswire
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE
Jul-02-18 07:30AM  A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More? ACCESSWIRE
Jun-15-18 07:09AM  Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar ACCESSWIRE
Jun-14-18 08:39AM  Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1% Zacks
Jun-07-18 08:01AM  Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma GlobeNewswire -6.09%
Jun-05-18 11:30AM  Iovance Biotherapeutics Inc (NASDAQ:IOVA): When Will It Breakeven? Simply Wall St.
08:46AM  Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options Zacks
May-31-18 08:01AM  Iovance Biotherapeutics to Present at Two Investor Conferences in June GlobeNewswire
May-29-18 08:00AM  Report: Exploring Fundamental Drivers Behind ServisFirst Bancshares, Iovance Biotherapeutics, Inc., MarineMax, TriNet Group, Dorian LPG, and AAON New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
May-16-18 10:47AM  4 Small Speculative Names on My Radar TheStreet.com +7.87%
May-15-18 07:10AM  Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration ACCESSWIRE
May-14-18 07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-11-18 11:45AM  RXII: Partner Relationships in TILs to Drive Future Value Zacks Small Cap Research
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dukes Iain D.DirectorDec 18Buy8.6512,000103,79612,000Dec 20 05:00 PM
MCPEAK MERRILL ADirectorDec 13Buy9.6310,00096,273456,583Dec 14 05:00 PM
Rothbaum Wayne P.DirectorDec 06Buy9.86300,0002,958,0007,067,333Dec 07 04:32 PM
Rothbaum Wayne P.DirectorDec 04Buy10.31921,0539,496,0566,767,333Dec 07 04:32 PM
open in yahoo | open in reuters | open in google